ST 045849

Key Product Details

Product Description

ST 045849 is an O-GlcNAc transferase (OGT) inhibitor (IC₅₀ = 53 μM). Reduces proliferation and viability of prostate cancer cells in vitro. Depletes intracellular alanine and decreases glucose consumption by cancer cells. Decreases markers of ER stress and apoptosis in pregnant diabetic mice and reduces neural tube defects in embryos from diabetic mice.

Product Specifications for ST 045849

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for ST 045849

The following data is based on the product molecular weight 446.99.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.24 mL	11.19 mL	22.37 mL
5 mM	0.45 mL	2.24 mL	4.47 mL
10 mM	0.22 mL	1.12 mL	2.24 mL
50 mM	0.04 mL	0.22 mL	0.45 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 3 publications citing the usage of this product.

• Kim Impact of protein O-GlcNAcylation on neural tube malformation in diabetic embryopathy. Sci.Rep. 2017 PMID: 28894244
• Kim Versatile O-GlcNAc transferase assay for high-throughput identification of enzyme variants, substrates, and inhibitors. Bioconjug.Chem. 2014 PMID: 24866374
• Itkonen Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism. Oncotarget 2016 PMID: 26824323

Product Documents for ST 045849